Blue Rabbit Vets Hop for Powerful Drug Import Approval
Published Date: 12/1/2025
Notice
Summary
Blue Rabbit Veterinary LLC wants to become an official importer of two strong veterinary drugs, Etorphine HCI and Thiafentanil, both Schedule II controlled substances. This means vets and animal care pros might get easier access to these important medicines soon. People and companies can share their thoughts or objections online by December 31, 2025, so don’t miss the deadline!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Importer applied to supply zoo/wildlife drugs
On October 28, 2025, Blue Rabbit Veterinary LLC applied to be registered to import Etorphine HCI (code 9059) and Thiafentanil (code 9729), both Schedule II controlled substances. If approved, the company plans to import those drugs in final dosage form for distribution to prospective zoo and wildlife customers.
Registration limited; commercial sale barred
The registration application is limited to the listed import activity and expressly states no other activities for these drug codes are authorized. The authorization will not extend to the import of FDA-approved or non‑approved finished dosage forms for commercial sale.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-21718 — Center for Scientific Review; Notice of Closed Meeting
The NIH’s Center for Scientific Review is holding a secret virtual meeting on December 19, 2025, to review important grant applications for research training. This meeting was delayed by a government shutdown but is now urgent to keep funding on track for key health projects. Researchers waiting on NIH money should pay attention because these reviews help decide who gets funded next.
Next: 2025-21720 — Bulk Manufacturer of Controlled Substances Application: Benuvia Operations, LLC
Benuvia Operations, LLC wants to become a big-time maker of some powerful drugs like LSD and codeine for research and making new medicine doses. If you have thoughts or concerns, you’ve got until January 30, 2026, to speak up or ask for a hearing. This move could speed up drug research but doesn’t change any sales or money rules right now.